Considerations To Know About Sifalimumab
MI-CP151 was a period 1b randomised, double-blind, placebo managed, dose-escalation, multicentre study To guage a number of intravenous doses of sifalimumab, in adult people with dermatomyositis or polymyositis (NCT00533091). Key trial aims had been To judge the security and tolerability of sifalimumab in dermatomyositis or polymyositis individuals